Holdings
Sands Capital Alternatives, LLC
As of Sep 30, 2026, Sands Capital Alternatives, LLC reported 23 positions worth US$689M. Largest: Alamar Biosciences, Inc., Nu Holdings Ltd. and Beta Bionics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Alamar Biosciences, Inc. | 4.23M | US$144M | no change | Sep 30, 2026 |
| Nu Holdings Ltd. | 6.99M | US$88.5M | −103K | Sep 30, 2026 |
| Beta Bionics, Inc. | 4M | US$75.9M | +290K | Sep 30, 2026 |
| SpyGlass Pharma, Inc. | 2.5M | US$65M | no change | Sep 30, 2026 |
| Klaviyo, Inc. Series A | 3.83M | US$60.2M | −101K | Sep 30, 2026 |
| 10x Genomics, Inc. | 482K | US$43.5M | no change | Sep 30, 2026 |
| Inhibikase Therapeutics, Inc. | 13M | US$26.8M | no change | Sep 30, 2026 |
| Cerebras Systems Inc. | 122K | US$21.8M | +89,659 | Sep 30, 2026 |
| DoorDash, Inc. | 107K | US$19.7M | −20,261 | Sep 30, 2026 |
| Odyssey Therapeutics, Inc. | 875K | US$19.4M | no change | Sep 30, 2026 |